MPAX

MPAX is a clinical-stage biotechnology company dedicated to transforming cancer treatment through its innovative Multi-Payload Adenoviral eXpression (MPAX) platform. The company specializes in developing oncolytic adenoviruses engineered to deliver potent immune-stimulating payloads directly into tumors, thereby activating a systemic anti-cancer response. Its lead therapeutic candidate, MEM-288, is an investigational agent that expresses both interferon-beta and CD40 ligand to promote dendritic cell maturation and T-cell activation. Currently in Phase 1/2 clinical trials, MEM-288 is being studied for its efficacy in treating various solid tumors, including non-small cell lung cancer and pancreatic cancer. By leveraging its proprietary platform, MPAX aims to create a new class of immunotherapies that can overcome the immunosuppressive nature of the tumor microenvironment. The company is headquartered in Houston, Texas, and maintains strategic collaborations with leading cancer research institutions like the Moffitt Cancer Center.